2-bromo-3-(5-benzyloxy-1H-indol-3-yl)-N-benzyloxymethylmaleimide | 220873-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-bromo-3-(5-benzyloxy-1H-indol-3-yl)-N-benzyloxymethylmaleimide
• 英文别名: 3-bromo-4-(5-phenylmethoxy-1H-indol-3-yl)-1-(phenylmethoxymethyl)pyrrole-2,5-dione
• CAS: 220873-35-8
• 化学式: C₂₇H₂₁BrN₂O₄
• 分子量: 517.379
• InChiKey: FOLXFUZLJBNJGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-bromo-3-(5-benzyloxy-1H-indol-3-yl)-N-benzyloxymethylmaleimide 在 甲基碘化镁 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 3-(5-Benzyloxy-1H-indol-3-yl)-1-benzyloxymethyl-4-[5-benzyloxy-1-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
  参考文献：
  名称：

  Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110

  摘要：

  All four "symmetrical" regioisomers of ED-110, an indolocarbazole derivative having potent activity against human topoisomerase I (Topo I) were synthesized. The isomer containing hydroxyl groups in the 3- and 9-positions was approximately ten-fold more active against Topo I, and 5- to 35-fold more active against human solid tumor cell lines in vitro, relative to ED-110. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00710-0
• 作为产物：
  描述：

  5-苄氧基吲哚 、 N-benzyloxymethyl-3,4-dibromomaleimide 在 甲基碘化镁 作用下， 生成 2-bromo-3-(5-benzyloxy-1H-indol-3-yl)-N-benzyloxymethylmaleimide
  参考文献：
  名称：

  Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110

  摘要：

  All four "symmetrical" regioisomers of ED-110, an indolocarbazole derivative having potent activity against human topoisomerase I (Topo I) were synthesized. The isomer containing hydroxyl groups in the 3- and 9-positions was approximately ten-fold more active against Topo I, and 5- to 35-fold more active against human solid tumor cell lines in vitro, relative to ED-110. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00710-0

文献信息

• Indolocarbazole anticancer agents and methods of using them
  申请人：Advanced Life Sciences, Inc.

  公开号：US20030087842A1

  公开（公告）日：2003-05-08

  The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity. 1

  本发明涉及抗肿瘤化合物、组合物和方法。具体而言，该发明涉及以下通式的吲哚咔唑类似物，其抑制拓扑异构酶I活性。
• Indolocarbazole anticancer agents and methods of using same
  申请人：Advanced Life Sciences, Inc.

  公开号：US20040077554A1

  公开（公告）日：2004-04-22

  The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity. 1

  本发明涉及抗肿瘤化合物、组合物和方法。具体而言，本发明涉及抑制拓扑异构酶I活性的以下一般公式的吲哚咔唑类似物。
• INDOLOCARBAZOLE ANTICANCER AGENTS AND METHODS OF USING THEM
  申请人：Advanced Life Sciences, Inc.

  公开号：EP1341412A1

  公开（公告）日：2003-09-10
• EP1646380A4
  申请人：——

  公开号：EP1646380A4

  公开（公告）日：2009-03-11
• INDOLOCARBAZOLE ANTICANCER AGENTS AND METHODS OF USING SAME
  申请人：Advanced Life Sciences Inc.

  公开号：EP1646380A2

  公开（公告）日：2006-04-19